Last reviewed · How we verify
NCT04565106: O2matic-COVI
Automatic Oxygen Titration With O2matic® to Patients Admitted With COVID-19 and Hypoxemic Respiratory Failure
trial testing Closed-loop control of oxygen supplementation by O2matic in Covid19 in 16 participants. Completed in 31 May 2020.
31 May 2020
Quick facts
| Lead sponsor | Hvidovre University Hospital |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 16 |
| Start date | 15 April 2020 |
| Primary completion | 31 May 2020 |
| Estimated completion | 31 May 2020 |
| Sites | 1 location across Denmark |
Drugs / interventions tested
- Closed-loop control of oxygen supplementation by O2matic
Conditions studied
- Covid19 — all drugs for Covid19 →
- Hypoxemic Respiratory Failure — all drugs for Hypoxemic Respiratory Failure →
- Hypoxemia — all drugs for Hypoxemia →
Sponsor
Hvidovre University Hospital
Who can join
18 and older, any sex, with Covid19 or Hypoxemic Respiratory Failure. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Patients with coronavirus disease (COVID-19) and pneumonitis often have hypoxemic respiratory failure and a need of supplementary oxygen. Guidelines recommend controlled oxygen, for most patients with a recommended interval of SpO2 between 92 and 96 %. We aimed to determine if closed-loop control of oxygen was feasible in patients with COVID-19 and could maintain SpO2 in the specified interval.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04565106
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Covid19
Currently open trials in the same condition.
- NCT03305341 — Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix · EARLY_PHASE1 · active not recruiting
- NCT06482138 — Dysfunction of Olfaction After COVID-19 Infection: Morphological and Histomolecular Investigation · NA · recruiting
- NCT04924803 — Community Developed Technology-Based Messaging to Increase COVID-19 Vaccine Uptake Among People Who Inject Drugs · NA · active not recruiting
- NCT05013632 — COVID-19 International Drug Pregnancy Registry · recruiting
- NCT04806061 — Urine Alkalinisation in COVID-19 · NA · active not recruiting
Other Hvidovre University Hospital trials
Trials by the same sponsor.
- NCT07561164 — Feasibility of a Co-designed Mobility Intervention After Hip Fracture Surgery · NA · not yet recruiting
- NCT06909240 — Progressive Gait Training After First-time Deep Venous Thrombosis: Clinical Effectiveness and Involved Mecanisms (The DV · NA · recruiting
- NCT07054216 — Probiotic for Infants · NA · recruiting
- NCT07029334 — Effectiveness Evaluation of Social Prescribing · recruiting
- NCT06789484 — Characterization of the Gastrointestinal Microbiota in Newborn Infants · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04565106 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hvidovre University Hospital
- Last refreshed: 25 September 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04565106.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing